98. 好酸球性消化管疾患 Disease details / Clinical trials / Drug dev / DR info

0.5 MG budesonide effervescent tablet FOR orodispersible USE
   Dr. Falk Pharma GmbH
      2017   Phase 3   EUCTR2014-001485-99-DK   Belgium;Denmark;Netherlands;Spain;Switzerland;United Kingdom
      2016   Phase 3   EUCTR2014-001485-99-NL   Belgium;Denmark;Germany;Netherlands;Spain;Switzerland;United Kingdom
      2016   Phase 3   EUCTR2014-001485-99-ES   Belgium;Denmark;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2016   Phase 3   EUCTR2014-001485-99-BE   Belgium;Denmark;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2015   Phase 3   EUCTR2014-001485-99-GB   Belgium;Denmark;Germany;Netherlands;Spain;Switzerland;United Kingdom
      2015   Phase 3   EUCTR2014-001485-99-DE   Belgium;Denmark;Germany;Netherlands;Spain;Switzerland;United Kingdom
1 food elimination diet
   Children's Hospital Medical Center, Cincinnati
      2016   Phase 2/Phase 3   NCT02610816   United States
1 food elimination diet therapy
   Children's Hospital Medical Center, Cincinnati
      2016   Phase 2/Phase 3   NCT02778867   United States
1 MG budesonide effervescent tablet FOR orodispersible USE
   Dr. Falk Pharma GmbH
      2017   Phase 3   EUCTR2014-001485-99-DK   Belgium;Denmark;Netherlands;Spain;Switzerland;United Kingdom
      2016   Phase 3   EUCTR2014-001485-99-NL   Belgium;Denmark;Germany;Netherlands;Spain;Switzerland;United Kingdom
      2016   Phase 3   EUCTR2014-001485-99-ES   Belgium;Denmark;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2016   Phase 3   EUCTR2014-001485-99-BE   Belgium;Denmark;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2015   Phase 3   EUCTR2014-001485-99-GB   Belgium;Denmark;Germany;Netherlands;Spain;Switzerland;United Kingdom
      2015   Phase 3   EUCTR2014-001485-99-DE   Belgium;Denmark;Germany;Netherlands;Spain;Switzerland;United Kingdom
      2015   Phase 3   EUCTR2014-001484-12-NL   Belgium;Germany;Netherlands;Spain;Switzerland
      2015   Phase 3   EUCTR2014-001484-12-ES   Belgium;Germany;Netherlands;Spain;Switzerland
      2015   Phase 3   EUCTR2014-001484-12-DE   Belgium;Germany;Netherlands;Spain;Switzerland
      2015   Phase 3   EUCTR2014-001484-12-BE   Belgium;Germany;Netherlands;Spain;Switzerland
1MG budesonide effervescent tablet FOR orodispersible USE
   Dr. Falk Pharma GmbH
      2012   Phase 2   EUCTR2009-016692-29-BE   Belgium;Germany;Switzerland
2MG budesonide effervescent tablet FOR orodispersible USE
   Dr. Falk Pharma GmbH
      2012   Phase 2   EUCTR2009-016692-29-BE   Belgium;Germany;Switzerland
4 food elimination diet
   Children's Hospital Medical Center, Cincinnati
      2016   Phase 2/Phase 3   NCT02610816   United States
5 MG montelukast
   Children's Mercy Hospital Kansas City
      2011   -   NCT01458418   United States
6 food elimination diet therapy
   Children's Hospital Medical Center, Cincinnati
      2016   Phase 2/Phase 3   NCT02778867   United States
AK002
   Allakos Inc.
      2021   Phase 3   NCT04856891   United States
      2020   Phase 2/Phase 3   NCT04322708   Australia;Netherlands;United States
      2020   Phase 3   NCT04322604   United States
      2020   Phase 2;Phase 3   EUCTR2019-004391-19-NL   Australia;Netherlands;United States
      2018   Phase 2   NCT03664960   United States
      2018   Phase 2   NCT03496571   United States
Alpha-proteinase inhibitor
   Children's Hospital Medical Center, Cincinnati
      2025   Phase 2   NCT05485155   United States
AMG 157
   AstraZeneca AB
      2023   Phase 3   EUCTR2022-001294-31-NL   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 3   EUCTR2022-001294-31-FI   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 3   EUCTR2022-001294-31-DE   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United States
      2023   Phase 3   EUCTR2022-001294-31-BE   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United States
      2022   Phase 3   EUCTR2022-001294-31-SK   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2022-001294-31-SE   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United States
      2022   Phase 3   EUCTR2022-001294-31-NO   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United States
      2022   Phase 3   EUCTR2022-001294-31-DK   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United States
      -   Phase 3   EUCTR2022-001294-31-GR   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United Kingdom;United States
      -   Phase 3   EUCTR2022-001294-31-AT   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United Kingdom;United States
AMG157
   ASTRAZENECA AB
      2022   Phase 3   EUCTR2022-001294-31-IT   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United States
   AstraZeneca AB
      2023   Phase 3   EUCTR2022-001294-31-NL   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 3   EUCTR2022-001294-31-FI   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 3   EUCTR2022-001294-31-DE   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United States
      2023   Phase 3   EUCTR2022-001294-31-BE   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United States
      2022   Phase 3   EUCTR2022-001294-31-SK   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2022-001294-31-SE   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United States
      2022   Phase 3   EUCTR2022-001294-31-NO   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United States
      2022   Phase 3   EUCTR2022-001294-31-DK   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United States
      -   Phase 3   EUCTR2022-001294-31-GR   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United Kingdom;United States
      -   Phase 3   EUCTR2022-001294-31-AT   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United Kingdom;United States
Antigen (wheat base SOY sauce) spray
   Mayo Clinic
      2015   -   NCT02434705   United States
APD334
   Arena Pharmaceuticals Inc.
      2021   Phase 2   EUCTR2020-003226-23-NL   Australia;Belgium;Germany;Netherlands;Spain;Switzerland;United States
      2021   Phase 2   EUCTR2020-003226-23-BE   Australia;Belgium;France;Germany;Netherlands;Spain;Switzerland;United States
   Arena Pharmaceuticals Inc., a wholly owned subsidiary of Pfizer Inc.
      2021   Phase 2   EUCTR2020-003226-23-DE   Australia;Belgium;France;Germany;Netherlands;Spain;Switzerland;United States
APT-1011
   Adare Pharmaceutical
      2017   Phase 2   EUCTR2016-004749-10-ES   Belgium;Canada;Germany;Spain;United States
      2017   Phase 2   EUCTR2016-004749-10-DE   Belgium;Canada;Germany;Spain;Switzerland;United States
      2017   Phase 2   EUCTR2016-004749-10-BE   Belgium;Canada;Germany;Spain;Switzerland;United States
   Adare Pharmaceuticals, Inc.
      2017   Phase 2   NCT03191864   Belgium;Canada;Germany;Spain;Switzerland;United States
   Ellodi Pharmaceuticals, LP
      2022   Phase 3   NCT05634746   Canada;United States
      2021   Phase 3   NCT05083312   Australia;United States
      2020   Phase 3   NCT04281108   Australia;Germany;Spain;United States
APT-1011 - 3 MG
   Adare Pharmaceuticals US, LP
      2020   Phase 3   EUCTR2019-001521-27-DE   Australia;Germany;Spain;United States
   Ellodi Pharmaceuticals, LP
      2020   Phase 3   EUCTR2019-001521-27-ES   Germany;Spain
APT-1011 3 MG HS
   Ellodi Pharmaceuticals, LP
      2022   -   NCT05095116   United States
AQ280
   AQILION AB
      2022   Phase 1   NCT05485779   United Kingdom
AR401959 L-arginine
   Arena Pharmaceuticals Inc.
      2021   Phase 2   EUCTR2020-003226-23-NL   Australia;Belgium;Germany;Netherlands;Spain;Switzerland;United States
      2021   Phase 2   EUCTR2020-003226-23-BE   Australia;Belgium;France;Germany;Netherlands;Spain;Switzerland;United States
   Arena Pharmaceuticals Inc., a wholly owned subsidiary of Pfizer Inc.
      2021   Phase 2   EUCTR2020-003226-23-DE   Australia;Belgium;France;Germany;Netherlands;Spain;Switzerland;United States
Assessment OF medication compliance
   Arkansas Children's Hospital Research Institute
      2019   -   NCT03615950   United States
Baked milk
   Mayo Clinic
      2022   -   NCT05606705   United States
Barium esophagram
   Mayo Clinic
      2017   -   NCT03290482   United States
Barzolvolimab
   CELLDEX THERAPEUTICS, INC
      2023   Phase 2   EUCTR2022-001786-12-IT   Australia;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States
   Celldex Therapeutics
      2023   Phase 2   NCT05774184   Australia;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States
   Celldex Therapeutics, Inc.
      2023   Phase 2   EUCTR2022-001786-12-PL   Australia;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States
      2023   Phase 2   EUCTR2022-001786-12-DE   Australia;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States
Beclomethasone dipropionate
   Penn State University
      2010   Phase 1   NCT01016223   United States
Benralizumab
   ASTRAZENECA AB
      2020   Phase 3   EUCTR2019-002871-32-IT   Canada;France;Germany;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
   Ageishi Yuji
      2022   Phase 3   JPRN-jRCT2031210500   America;Australia;Belgium;Brazil;Canada;China;France;Israel;Italy;Japan;Mexico;Netherlands;Poland;Spain;Ukraine;Vietnam
   AstraZeneca
      2022   Phase 3   NCT05251909   Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Ukraine;United States;Vietnam
      2020   Phase 3   NCT04543409   Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
   AstraZeneca AB
      2020   Phase 3   EUCTR2019-002871-32-NL   Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002871-32-GB   Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002871-32-FR   Canada;France;Germany;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002871-32-ES   Canada;France;Germany;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002871-32-DE   Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2019-002871-32-PL   Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
   Hibi Kazushige
      2020   Phase 3   JPRN-jRCT2061200026   Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russia;Spain;UK;US
Bethanechol
   University of Iowa
      2014   Phase 2   NCT02058537   United States
Blood sampling
   Assistance Publique - Hôpitaux de Paris
      2024   -   NCT06387030   France
Bone mineral density (dexa) scan
   Arkansas Children's Hospital Research Institute
      2019   -   NCT03615950   United States
BT-11 high
   NImmune Biopharma
      2022   Phase 1   NCT04835168   -
BT-11 LOW
   NImmune Biopharma
      2022   Phase 1   NCT04835168   -
Budesonide
   Dip. Pediatria UOC Gastroenterologia ed Epatologia Pediatrica
      -   Phase 2   EUCTR2014-002465-30-IT   Italy
   Dr. Falk Pharma GmbH
      2021   Phase 3   NCT06596252   Spain;United States
      2021   Phase 3   EUCTR2020-001314-37-PT   Austria;Canada;Germany;Portugal;Russian Federation;Spain;Switzerland
   IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA
      2019   Phase 2   EUCTR2019-002691-14-IT   Italy
   Istituto Clinico Humanitas
      2022   -   NCT05594849   Italy
   Mayo Clinic
      2008   Phase 2/Phase 3   NCT00728481   United States
   Shire
      2009   Phase 2   NCT00762073   United States
   Swiss EE Study Group
      2005   Phase 2   NCT00271349   Switzerland
   University Hospitals Cleveland Medical Center
      2021   Phase 4   NCT05444543   United States
Budesonide 0.5 MG compresse orodispersibili
   DR. FALK PHARMA GMBH
      2021   Phase 3   EUCTR2017-003516-39-IT   Germany;Italy;Spain;Switzerland
Budesonide 0.5 MG orodispersible tablets
   Dr. Falk Pharma GmbH
      2021   Phase 3   EUCTR2017-003516-39-ES   Germany;Italy;Spain;Switzerland
      2021   Phase 3   EUCTR2017-003516-39-DE   Germany;Italy;Spain;Switzerland
Budesonide 0.5MG orodispersible tablet twice daily
   Dr. Falk Pharma GmbH
      2016   Phase 3   NCT02493335   Germany
Budesonide 1 MG compresse orodispersibili
   DR. FALK PHARMA GMBH
      2021   Phase 3   EUCTR2017-003516-39-IT   Germany;Italy;Spain;Switzerland
Budesonide 1 MG orodispersible tablets
   Dr. Falk Pharma GmbH
      2021   Phase 3   EUCTR2020-001314-37-DE   Austria;Canada;Germany;Portugal;Russian Federation;Spain;Switzerland
      2021   Phase 3   EUCTR2020-001314-37-AT   Austria;Canada;Germany;Portugal;Russian Federation;Spain;Switzerland
      2021   Phase 3   EUCTR2017-003516-39-ES   Germany;Italy;Spain;Switzerland
      2021   Phase 3   EUCTR2017-003516-39-DE   Germany;Italy;Spain;Switzerland
Budesonide 1MG orodispersible tablet twice daily
   Dr. Falk Pharma GmbH
      2016   Phase 3   NCT02493335   Germany
      2015   Phase 3   NCT02434029   Germany
Budesonide [0.4MG/ML] viscous suspension
   Dr. Falk Pharma GmbH
      2012   Phase 2   EUCTR2009-016692-29-BE   Belgium;Germany;Switzerland
Budesonide GEL
   Bazell Pharma AG
      2021   Phase 2   NCT05214599   -
Budesonide oral suspension
   Dr. Falk Pharma GmbH
      2020   Phase 2;Phase 3   EUCTR2017-003737-29-NL   Germany;Greece;Israel;Netherlands;Portugal;Spain;United Kingdom
      2019   Phase 2;Phase 3   EUCTR2017-003737-29-PT   Germany;Greece;Israel;Netherlands;Portugal;Spain;United Kingdom
      2019   Phase 2;Phase 3   EUCTR2017-003737-29-GR   Germany;Greece;Israel;Netherlands;Portugal;Spain;United Kingdom
      2019   Phase 2;Phase 3   EUCTR2017-003737-29-GB   Germany;Greece;Israel;Netherlands;Portugal;Spain;United Kingdom
      2019   Phase 2;Phase 3   EUCTR2017-003737-29-ES   Germany;Greece;Israel;Netherlands;Portugal;Spain;United Kingdom
      -   Phase 2;Phase 3   EUCTR2017-003737-29-DE   Germany;Greece;Israel;Netherlands;Portugal;Spain;United Kingdom
   Shire
      2017   Phase 3   NCT03245840   United States
Budesonide plus prevacid
   Ranjan Dohil
      2008   Phase 2   NCT00638456   United States
Buet 0.5 MG
   DR. FALK PHARMA GMBH
      2017   Phase 3   EUCTR2014-001485-99-IT   Belgium;Denmark;Eswatini;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
   Dr. Falk Pharma GmbH
      2017   Phase 3   EUCTR2014-001485-99-DK   Belgium;Denmark;Netherlands;Spain;Switzerland;United Kingdom
      2016   Phase 3   EUCTR2014-001485-99-NL   Belgium;Denmark;Germany;Netherlands;Spain;Switzerland;United Kingdom
      2016   Phase 3   EUCTR2014-001485-99-ES   Belgium;Denmark;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2016   Phase 3   EUCTR2014-001485-99-BE   Belgium;Denmark;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2015   Phase 3   EUCTR2014-001485-99-GB   Belgium;Denmark;Germany;Netherlands;Spain;Switzerland;United Kingdom
      2015   Phase 3   EUCTR2014-001485-99-DE   Belgium;Denmark;Germany;Netherlands;Spain;Switzerland;United Kingdom
Buet 1 MG
   DR. FALK PHARMA GMBH
      2017   Phase 3   EUCTR2014-001485-99-IT   Belgium;Denmark;Eswatini;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
   Dr. Falk Pharma GmbH
      2012   Phase 2   EUCTR2009-016692-29-BE   Belgium;Germany;Switzerland
Buet 1MG
   Dr. Falk Pharma GmbH
      2017   Phase 3   EUCTR2014-001485-99-DK   Belgium;Denmark;Netherlands;Spain;Switzerland;United Kingdom
      2016   Phase 3   EUCTR2014-001485-99-NL   Belgium;Denmark;Germany;Netherlands;Spain;Switzerland;United Kingdom
      2016   Phase 3   EUCTR2014-001485-99-ES   Belgium;Denmark;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2016   Phase 3   EUCTR2014-001485-99-BE   Belgium;Denmark;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2015   Phase 3   EUCTR2014-001485-99-GB   Belgium;Denmark;Germany;Netherlands;Spain;Switzerland;United Kingdom
      2015   Phase 3   EUCTR2014-001485-99-DE   Belgium;Denmark;Germany;Netherlands;Spain;Switzerland;United Kingdom
      2015   Phase 3   EUCTR2014-001484-12-NL   Belgium;Germany;Netherlands;Spain;Switzerland
      2015   Phase 3   EUCTR2014-001484-12-ES   Belgium;Germany;Netherlands;Spain;Switzerland
      2015   Phase 3   EUCTR2014-001484-12-DE   Belgium;Germany;Netherlands;Spain;Switzerland
      2015   Phase 3   EUCTR2014-001484-12-BE   Belgium;Germany;Netherlands;Spain;Switzerland
      2012   Phase 2   EUCTR2009-016692-29-BE   Belgium;Germany;Switzerland
Buet 2MG
   Dr. Falk Pharma GmbH
      2012   Phase 2   EUCTR2009-016692-29-BE   Belgium;Germany;Switzerland
BUL 0.5 MG
   DR. FALK PHARMA GMBH
      2021   Phase 3   EUCTR2017-003516-39-IT   Germany;Italy;Spain;Switzerland
   Dr. Falk Pharma GmbH
      2021   Phase 3   EUCTR2017-003516-39-ES   Germany;Italy;Spain;Switzerland
      2021   Phase 3   EUCTR2017-003516-39-DE   Germany;Italy;Spain;Switzerland
BUL 1 MG
   DR. FALK PHARMA GMBH
      2021   Phase 3   EUCTR2017-003516-39-IT   Germany;Italy;Spain;Switzerland
   Dr. Falk Pharma GmbH
      2021   Phase 3   EUCTR2020-001314-37-DE   Austria;Canada;Germany;Portugal;Russian Federation;Spain;Switzerland
      2021   Phase 3   EUCTR2020-001314-37-AT   Austria;Canada;Germany;Portugal;Russian Federation;Spain;Switzerland
      2021   Phase 3   EUCTR2017-003516-39-ES   Germany;Italy;Spain;Switzerland
      2021   Phase 3   EUCTR2017-003516-39-DE   Germany;Italy;Spain;Switzerland
BUU 0.4MG/ML
   Dr. Falk Pharma GmbH
      2012   Phase 2   EUCTR2009-016692-29-BE   Belgium;Germany;Switzerland
CALY-002
   Calypso Biotech BV
      2020   Phase 1   NCT04593251   Belgium;Finland;Germany;Netherlands;Norway
CC-93538
   CELGENE INTERNATIONAL II SàRL
      2022   Phase 3   EUCTR2020-004335-24-IT   Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004336-16-IT   Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
   Celgene
      2022   Phase 3   NCT05214768   Japan
      2021   Phase 3   NCT04991935   Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
      2021   Phase 3   NCT04753697   Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Puerto Rico;Spain;Switzerland;United Kingdom;United States
   Celgene International II Sàrl
      2022   Phase 3   EUCTR2020-004336-16-ES   Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004335-24-PT   Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004335-24-PL   Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004335-24-ES   Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004335-24-DE   Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004335-24-BE   Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004335-24-AT   Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004336-16-PT   Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004336-16-PL   Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004336-16-DE   Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004336-16-BE   Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004336-16-AT   Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
CDX-0159
   CELLDEX THERAPEUTICS, INC
      2023   Phase 2   EUCTR2022-001786-12-IT   Australia;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States
   Celldex Therapeutics, Inc.
      2023   Phase 2   EUCTR2022-001786-12-PL   Australia;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States
      2023   Phase 2   EUCTR2022-001786-12-DE   Australia;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States
Cendakimab
   CELGENE INTERNATIONAL II SàRL
      2022   Phase 3   EUCTR2020-004335-24-IT   Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004336-16-IT   Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
   Celgene
      2022   Phase 1   NCT05175352   United States
   Celgene International II Sàrl
      2022   Phase 3   EUCTR2020-004336-16-ES   Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004335-24-PT   Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004335-24-PL   Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004335-24-ES   Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004335-24-DE   Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004335-24-BE   Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004335-24-AT   Argentina;Australia;Austria;Belgium;Canada;Germany;Israel;Italy;Japan;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004336-16-PT   Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004336-16-PL   Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004336-16-DE   Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004336-16-BE   Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004336-16-AT   Argentina;Australia;Austria;Belgium;Canada;Czechia;Germany;Israel;Italy;Japan;New Zealand;Poland;Portugal;Spain;Switzerland;United Kingdom;United States
Citalopram
   Amsterdam UMC
      2021   Phase 4   EUCTR2021-002288-24-NL   Netherlands
Compressa effervescente 0,5 MG DI budesonide PER USO orodispersibile
   DR. FALK PHARMA GMBH
      2017   Phase 3   EUCTR2014-001485-99-IT   Belgium;Denmark;Eswatini;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
Compressa effervescente 1 MG DI budesonide PER USO orodispersibile
   DR. FALK PHARMA GMBH
      2017   Phase 3   EUCTR2014-001485-99-IT   Belgium;Denmark;Eswatini;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
Computerized tomography scan
   University of Utah
      2016   Early Phase 1   NCT04069429   United States
Cortisol level
   University of Colorado, Denver
      2022   -   NCT05246085   United States
CYP substrates
   Celgene
      2022   Phase 1   NCT05175352   United States
D-xylose
   Mayo Clinic
      2014   -   NCT02314455   United States
Dexlansoprazole
   Mayo Clinic
      2012   Phase 1/Phase 2   NCT01479231   United States
Dose
   Ageishi Yuji
      2023   Phase 3   JPRN-jRCT2021230017   Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United Kingdom;United Sates
      2022   Phase 3   JPRN-jRCT2031210500   America;Australia;Belgium;Brazil;Canada;China;France;Israel;Italy;Japan;Mexico;Netherlands;Poland;Spain;Ukraine;Vietnam
   Ann & Robert H Lurie Children's Hospital of Chicago
      2014   -   NCT05309590   United States
   AstraZeneca AB
      2020   Phase 3   EUCTR2019-002871-32-GB   Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002871-32-FR   Canada;France;Germany;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002871-32-DE   Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
   Shabbir Arsalan Q.
      2024   Phase 2-3   JPRN-jRCT2031230539   Australia;Canada;France;Italy;Japan;Poland;US
Dupilumab
   Children's Hospital Medical Center, Cincinnati
      2021   Phase 2   NCT03678545   United States
   Children's Hospital of Philadelphia
      2022   Phase 4   NCT05247866   United States
   Regeneron Pharmaceuticals
      2024   -   NCT06693531   United States
      2023   Phase 2   NCT05831176   Australia;Canada;Italy;Japan;Poland;United States
      2020   Phase 3   NCT04394351   Canada;United States
      2018   Phase 3   NCT03633617   Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States
      2015   Phase 2   NCT02379052   United States
   Regeneron Pharmaceuticals, Inc.
      2019   Phase 3   EUCTR2018-000844-25-SE   Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-000844-25-PT   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-000844-25-NL   Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-000844-25-IT   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-000844-25-GB   Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-000844-25-FR   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-000844-25-ES   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-000844-25-DE   Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-000844-25-BE   Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
   Sanofi
      2024   -   NCT06695897   Germany
      2023   Phase 4   NCT06101095   Brazil;Canada;Israel;Switzerland;United States
   Shabbir Arsalan Q.
      2024   Phase 2-3   JPRN-jRCT2031230539   Australia;Canada;France;Italy;Japan;Poland;US
   University of California, San Diego
      2024   Phase 4   NCT06665971   United States
   University of Colorado, Denver
      2024   Phase 2   NCT06705387   United States
   University of North Carolina, Chapel Hill
      2024   Phase 4   NCT06352073   United States
Dupixent
   Regeneron Pharmaceuticals, Inc.
      2019   Phase 3   EUCTR2018-000844-25-SE   Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-000844-25-PT   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-000844-25-NL   Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-000844-25-IT   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-000844-25-GB   Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-000844-25-FR   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-000844-25-ES   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-000844-25-DE   Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
      2019   Phase 3   EUCTR2018-000844-25-BE   Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States
   University of California, San Diego
      2024   Phase 4   NCT06665971   United States
Elimination diet
   Baylor College of Medicine
      2013   Phase 2   NCT01821898   United States
Else nutrition formula
   Rambam Health Care Campus
      2022   -   NCT05622214   Israel
Endoscopy while ON study drug
   Claire Daniels
      2018   Phase 4   NCT03781596   United States
Eosinophilic esophagitis (E0E) food introduction-2ND
   Children's Hospital of Philadelphia
      2022   Phase 4   NCT05247866   United States
Eosinophilic esophagitis (EOE) food introduction-1ST
   Children's Hospital of Philadelphia
      2022   Phase 4   NCT05247866   United States
Eosinophilic esophagitis (EOE) food introduction-3RD dose
   Children's Hospital of Philadelphia
      2022   Phase 4   NCT05247866   United States
EP-104IAR
   Eupraxia Pharmaceuticals Inc.
      2023   Phase 1/Phase 2   NCT05608681   Australia;Canada;Netherlands
ESO-101
   EsoCap AG
      2023   Phase 2   EUCTR2020-000082-16-PL   Germany;Netherlands;Poland;Spain;Switzerland
      2021   Phase 2   NCT04849390   Germany;Netherlands;Poland;Spain;Switzerland
      2021   Phase 2   EUCTR2020-000082-16-DE   Germany;Netherlands;Poland;Spain;Switzerland
      2020   Phase 2   EUCTR2020-000082-16-NL   Germany;Netherlands;Poland;Spain;Switzerland
Esomeprazole
   Mayo Clinic
      2008   Phase 2/Phase 3   NCT00728481   United States
   University of Utah
      2004   Phase 2   NCT00123656   United States
   Walter Reed Army Medical Center
      2008   -   NCT00895817   United States
Esophacap
   Mayo Clinic
      2017   -   NCT03290482   United States
Esophageal barium xray
   Mayo Clinic
      2013   -   NCT01865825   United States
Esophageal biopsies
   Assistance Publique - Hôpitaux de Paris
      2024   -   NCT06387030   France
Esophageal dilation
   Vanderbilt University
      2008   -   NCT00880906   United States
Esophagogastroduodenoscopy
   Ellodi Pharmaceuticals, LP
      2022   Phase 3   NCT05634746   Canada;United States
      2020   Phase 3   NCT04281108   Australia;Germany;Spain;United States
   University of Utah
      2016   Early Phase 1   NCT04069429   United States
Etrasimod
   Pfizer
      2020   Phase 2   NCT04682639   Australia;Belgium;Canada;Germany;Netherlands;Spain;Switzerland;United States
Etrasimod L-arginine
   Arena Pharmaceuticals Inc.
      2021   Phase 2   EUCTR2020-003226-23-NL   Australia;Belgium;Germany;Netherlands;Spain;Switzerland;United States
      2021   Phase 2   EUCTR2020-003226-23-BE   Australia;Belgium;France;Germany;Netherlands;Spain;Switzerland;United States
   Arena Pharmaceuticals Inc., a wholly owned subsidiary of Pfizer Inc.
      2021   Phase 2   EUCTR2020-003226-23-DE   Australia;Belgium;France;Germany;Netherlands;Spain;Switzerland;United States
EUR-1100
   Aptalis Pharma
      2011   Phase 1/Phase 2   NCT01386112   United States
   Forest Laboratories
      2012   -   NCT01498497   United States
Famotidine
   Mayo Clinic
      2020   Phase 2   NCT04248712   United States
Fasenra
   AstraZeneca AB
      2020   Phase 3   EUCTR2019-002871-32-NL   Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002871-32-DE   Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
Florence 30 µG/ML
   EMS
      2021   Phase 2   NCT02873468   Brazil
Florence 60 µG/ML
   EMS
      2021   Phase 2   NCT02873468   Brazil
Florence 90 µG/ML
   EMS
      2021   Phase 2   NCT02873468   Brazil
Flovent
   Marc Rothenberg, MD
      2007   Phase 2   NCT00426283   United States
Fluticasone
   Azienda Policlinico Umberto I
      2012   Phase 4   NCT01846962   Italy
   Claire Daniels
      2018   Phase 4   NCT03781596   United States
   Mayo Clinic
      2005   Phase 2   NCT00275561   United States
   Medical College of Wisconsin
      2012   Phase 3   NCT01702701   United States
   Technical University of Munich
      2011   -   NCT01624129   Germany
   University of Colorado, Denver
      2024   Phase 2   NCT06705387   United States
   University of Utah
      2004   Phase 2   NCT00123656   United States
Fluticasone MDI
   University of North Carolina, Chapel Hill
      2015   Phase 4   NCT02019758   United States
Fluticasone propionate
   Adare Pharmaceutical
      2017   Phase 2   EUCTR2016-004749-10-ES   Belgium;Canada;Germany;Spain;United States
      2017   Phase 2   EUCTR2016-004749-10-DE   Belgium;Canada;Germany;Spain;Switzerland;United States
      2017   Phase 2   EUCTR2016-004749-10-BE   Belgium;Canada;Germany;Spain;Switzerland;United States
   Children's Hospital Medical Center, Cincinnati
      2016   Phase 2/Phase 3   NCT02778867   United States
      2016   Phase 2/Phase 3   NCT02610816   United States
   Marc Rothenberg
      2002   Phase 3   NCT00266578   United States
   University Hospitals Cleveland Medical Center
      2021   Phase 4   NCT05444543   United States
Fluticasone propionate, USP
   Adare Pharmaceuticals US, LP
      2020   Phase 3   EUCTR2019-001521-27-DE   Australia;Germany;Spain;United States
   Ellodi Pharmaceuticals, LP
      2020   Phase 3   EUCTR2019-001521-27-ES   Germany;Spain
Formalin-fixed paraffin-embedded (ffpe) tissue samples analysis
   IRCCS San Raffaele
      2023   -   NCT06071585   Italy
Gastrointestinal quality OF life index
   Wroclaw Medical University
      2017   -   NCT04803162   Poland
Height measurement
   Arkansas Children's Hospital Research Institute
      2019   -   NCT03615950   United States
High dose budesonide suspension
   Dr. Falk Pharma GmbH
      2011   Phase 2   NCT02280616   Germany
High dose budesonide tablet
   Dr. Falk Pharma GmbH
      2011   Phase 2   NCT02280616   Germany
HIGH-resolution manometry
   Wroclaw Medical University
      2017   -   NCT04803162   Poland
Honey
   Walter Reed National Military Medical Center
      2014   -   NCT02125851   United States
Humanised IGG1K monoclonal antibody against KIT
   Celldex Therapeutics, Inc.
      2023   Phase 2   EUCTR2022-001786-12-PL   Australia;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States
      2023   Phase 2   EUCTR2022-001786-12-DE   Australia;Canada;Germany;Italy;Poland;Spain;United Kingdom;United States
Infliximab
   Swiss EE Study Group
      2007   Phase 2   NCT00523354   Switzerland
Inhaled/swallowed budesonide
   University of North Carolina, Chapel Hill
      2009   -   NCT00961233   United States
Intraluminal impedance
   Mayo Clinic
      2015   Early Phase 1   NCT02353078   United States
IRL201104
   Revolo Biotherapeutics
      2021   Phase 2   NCT05084963   United States
Jorveza
   Dr. Falk Pharma GmbH
      2021   Phase 3   EUCTR2020-001314-37-DE   Austria;Canada;Germany;Portugal;Russian Federation;Spain;Switzerland
      2021   Phase 3   EUCTR2020-001314-37-AT   Austria;Canada;Germany;Portugal;Russian Federation;Spain;Switzerland
   Istituto Clinico Humanitas
      2022   -   NCT05594849   Italy
Jorveza 0.5 MG compresse orodispersibili
   DR. FALK PHARMA GMBH
      2021   Phase 3   EUCTR2017-003516-39-IT   Germany;Italy;Spain;Switzerland
Jorveza 0.5 MG orodispersible tablets
   Dr. Falk Pharma GmbH
      2021   Phase 3   EUCTR2017-003516-39-ES   Germany;Italy;Spain;Switzerland
      2021   Phase 3   EUCTR2017-003516-39-DE   Germany;Italy;Spain;Switzerland
Jorveza 1 MG compresse orodispersibili
   DR. FALK PHARMA GMBH
      2021   Phase 3   EUCTR2017-003516-39-IT   Germany;Italy;Spain;Switzerland
Jorveza 1 MG orodispersible tablets
   Dr. Falk Pharma GmbH
      2021   Phase 3   EUCTR2020-001314-37-PT   Austria;Canada;Germany;Portugal;Russian Federation;Spain;Switzerland
      2021   Phase 3   EUCTR2017-003516-39-ES   Germany;Italy;Spain;Switzerland
      2021   Phase 3   EUCTR2017-003516-39-DE   Germany;Italy;Spain;Switzerland
Lirentelimab
   Allakos Inc.
      2020   Phase 3   NCT04620811   United States
      2020   Phase 2/Phase 3   NCT04322708   Australia;Netherlands;United States
      2020   Phase 3   NCT04322604   United States
Loratadine
   Mayo Clinic
      2020   Phase 2   NCT04248712   United States
Losartan potassium
   Children's Hospital Medical Center, Cincinnati
      2017   Phase 2   NCT03029091   United States
      2013   Phase 2   NCT01808196   United States
LOW dose budesonide tablet
   Dr. Falk Pharma GmbH
      2011   Phase 2   NCT02280616   Germany
MEDI-563
   ASTRAZENECA AB
      2020   Phase 3   EUCTR2019-002871-32-IT   Canada;France;Germany;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
   AstraZeneca AB
      2020   Phase 3   EUCTR2019-002871-32-NL   Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002871-32-GB   Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002871-32-FR   Canada;France;Germany;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002871-32-ES   Canada;France;Germany;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2019-002871-32-DE   Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2019-002871-32-PL   Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
MEDI9929
   ASTRAZENECA AB
      2022   Phase 3   EUCTR2022-001294-31-IT   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United States
   AstraZeneca AB
      2023   Phase 3   EUCTR2022-001294-31-NL   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 3   EUCTR2022-001294-31-FI   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 3   EUCTR2022-001294-31-DE   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United States
      2023   Phase 3   EUCTR2022-001294-31-BE   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United States
      2022   Phase 3   EUCTR2022-001294-31-SK   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2022-001294-31-SE   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United States
      2022   Phase 3   EUCTR2022-001294-31-NO   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United States
      2022   Phase 3   EUCTR2022-001294-31-DK   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United States
      -   Phase 3   EUCTR2022-001294-31-GR   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United Kingdom;United States
      -   Phase 3   EUCTR2022-001294-31-AT   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United Kingdom;United States
Medication compliance phone call
   Claire Daniels
      2018   Phase 4   NCT03781596   United States
Mepolizumab
   Children's Hospital Medical Center, Cincinnati
      2001   Phase 1/Phase 2   NCT00266565   United States
   GlaxoSmithKline
      2006   Phase 2   NCT00358449   Australia;Canada;United Kingdom;United States
   GlaxoSmithKline Research & Development Ltd.
      2006   Phase 2   EUCTR2005-006074-10-GB   United Kingdom
Mepolizumab 100 MG
   University of North Carolina, Chapel Hill
      2019   Phase 2   NCT03656380   United States
Mepolizumab 300 MG
   University of North Carolina, Chapel Hill
      2019   Phase 2   NCT03656380   United States
Mesalamine oral product
   Dr. Falk Pharma GmbH
      2023   Phase 2   NCT05488405   Switzerland
Mometasone furoate
   EsoCap AG
      2023   Phase 2   EUCTR2020-000082-16-PL   Germany;Netherlands;Poland;Spain;Switzerland
      2021   Phase 2   EUCTR2020-000082-16-DE   Germany;Netherlands;Poland;Spain;Switzerland
      2020   Phase 2   EUCTR2020-000082-16-NL   Germany;Netherlands;Poland;Spain;Switzerland
   Mogens Bove
      2014   Phase 2   NCT02113267   Sweden
Montelukast
   Children's Mercy Hospital Kansas City
      2005   -   NCT00148603   United States
   Medical College of Wisconsin
      2012   Phase 3   NCT01702701   United States
Montelukast/ singulair
   Mayo Clinic
      2007   Phase 1   NCT00511316   United States
Nasonex
   NU-sjukvården, Norra Älvsborgs Länssjukhus
      2013   Phase 2   EUCTR2012-005842-39-SE   Sweden
NDX-3315 and NDX-3324
   NexEos Diagnostics, Inc.
      2023   Phase 2   NCT05757856   United States
Niox mino® airway inflammation monitor
   Tufts Medical Center
      2010   -   NCT01170234   United States
OC000459
   Oxagen Ltd
      2010   Phase 2   NCT01056783   Switzerland
Omalizumab
   National Institute of Allergy and Infectious Diseases (NIAID)
      2004   Phase 2   NCT00084097   United States
   O & O Alpan LLC
      2009   Phase 1   NCT01040598   United States
   University of Utah
      2005   Phase 2   NCT00123630   United States
Omeprazole
   Claire Daniels
      2018   Phase 4   NCT03781596   United States
Omeprazole 20 MG oral tablet
   Wroclaw Medical University
      2017   -   NCT04803162   Poland
Omeprazole 20MG BID
   University of Colorado, Denver
      2020   Phase 4   NCT04149470   United States
Ondansetron
   State University of New York - Downstate Medical Center
      2021   Phase 4   NCT05439772   United States
Oral budesonide
   Baylor College of Medicine
      2013   Phase 2   NCT01821898   United States
   Shire
      2016   Phase 3   NCT02736409   United Kingdom;United States
      2015   Phase 3   NCT02605837   United States
      2012   Phase 2   NCT01642212   United States
Oral cromolyn sodium
   University of Tennessee
      2014   Phase 4   NCT02371941   United States
Oral nitric oxide testing
   Mayo Clinic
      2013   -   NCT01929824   United States
Oral viscous budesonide
   Azienda Policlinico Umberto I
      2012   Phase 4   NCT01846962   Italy
   University of North Carolina, Chapel Hill
      2015   Phase 4   NCT02019758   United States
Physical examination and questionnaires
   Mayo Clinic
      2017   -   NCT03290482   United States
Planar images
   University of Utah
      2016   Early Phase 1   NCT04069429   United States
Propofol
   Children's Hospital Medical Center, Cincinnati
      2009   -   NCT02038894   United States
QAX576
   Novartis Pharmaceuticals
      2009   Phase 2   NCT01022970   United States
Reslizumab
   Ception Therapeutics
      2008   Phase 3   NCT00635089   Canada;United States
      2008   Phase 2/Phase 3   NCT00538434   Canada;United States
Retrospective evaluation OF endoscopy prior TO study drug
   Claire Daniels
      2018   Phase 4   NCT03781596   United States
RPC4046
   Celgene
      2014   Phase 2   NCT02098473   Canada;Switzerland;United States
Saline
   Ception Therapeutics
      2008   Phase 2/Phase 3   NCT00538434   Canada;United States
SB-240563
   GlaxoSmithKline Research & Development Ltd.
      2006   Phase 2   EUCTR2005-006074-10-GB   United Kingdom
SCH55700
   National Institute of Allergy and Infectious Diseases (NIAID)
      2001   Phase 2   NCT00017862   United States
Serum biomarkers
   Wroclaw Medical University
      2017   -   NCT04803162   Poland
Sevoflurane
   Children's Hospital Medical Center, Cincinnati
      2009   -   NCT02038894   United States
Single photon emission computed tomography scans
   University of Utah
      2016   Early Phase 1   NCT04069429   United States
Sirolimus
   National Institute of Allergy and Infectious Diseases (NIAID)
      2013   Phase 1   NCT01814059   United States
SIX-foods elimination diet
   Azienda Policlinico Umberto I
      2012   Phase 4   NCT01846962   Italy
Solrikitug high dose
   Uniquity One (UNI)
      2024   Phase 2   NCT06598462   Australia;United States
Solrikitug LOW dose
   Uniquity One (UNI)
      2024   Phase 2   NCT06598462   Australia;United States
Solrikitug MID dose
   Uniquity One (UNI)
      2024   Phase 2   NCT06598462   Australia;United States
Steroid and proton pump inhibitor therapy
   Vanderbilt University
      2008   -   NCT00880906   United States
Stool sampling
   Assistance Publique - Hôpitaux de Paris
      2024   -   NCT06387030   France
Sucralfate
   Mayo Clinic
      2015   Early Phase 1   NCT02353078   United States
Swallowed fluticasone
   Walter Reed Army Medical Center
      2008   -   NCT00895817   United States
Symptom survey
   Claire Daniels
      2018   Phase 4   NCT03781596   United States
Technetium TC 99M
   University of Utah
      2016   Early Phase 1   NCT04069429   United States
Tezepelumab
   Ageishi Yuji
      2023   Phase 3   JPRN-jRCT2021230017   Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United Kingdom;United Sates
   AstraZeneca
      2022   Phase 3   NCT05583227   Australia;Austria;Belgium;Brazil;Canada;China;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United Kingdom;United States
   The First Affiliated Hospital of Sun Yat-Sen University
      2024   Phase 3   ChiCTR2500096479   China
Tezepelumab apfs
   ASTRAZENECA AB
      2022   Phase 3   EUCTR2022-001294-31-IT   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United States
Tezepelumab VIA apfs
   AstraZeneca AB
      2023   Phase 3   EUCTR2022-001294-31-NL   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 3   EUCTR2022-001294-31-FI   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United Kingdom;United States
      2023   Phase 3   EUCTR2022-001294-31-DE   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United States
      2023   Phase 3   EUCTR2022-001294-31-BE   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United States
      2022   Phase 3   EUCTR2022-001294-31-SK   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United Kingdom;United States
      2022   Phase 3   EUCTR2022-001294-31-SE   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United States
      2022   Phase 3   EUCTR2022-001294-31-NO   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United States
      2022   Phase 3   EUCTR2022-001294-31-DK   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United States
      -   Phase 3   EUCTR2022-001294-31-GR   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United Kingdom;United States
      -   Phase 3   EUCTR2022-001294-31-AT   Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Slovakia;Spain;Sweden;United Kingdom;United States
Treat with lansoprazole 30 MG BID FOR 2 weeks, endoscopic examination with esophageal biopsy FOR patients with persistent symptoms
   Dallas VA Medical Center
      2007   Phase 4   NCT01404832   United States
Unstimulated saliva sampling
   Assistance Publique - Hôpitaux de Paris
      2024   -   NCT06387030   France
Urine sampling
   Assistance Publique - Hôpitaux de Paris
      2024   -   NCT06387030   France
Viaskin milk 500 MCG
   Children's Hospital of Philadelphia
      2015   Phase 2   NCT02579876   United States
Viscous/swallowed budesonide
   University of North Carolina, Chapel Hill
      2009   -   NCT00961233   United States
Vitamin D measurement
   Arkansas Children's Hospital Research Institute
      2019   -   NCT03615950   United States
Vonoprazan
   Phathom Pharmaceuticals, Inc.
      2025   Phase 2   NCT06851559   -
   Second department of Internal Medicine, Shimane University Faculty of Medicine
      2016   -   JPRN-UMIN000021041   Japan
Xanthan GUM
   Walter Reed National Military Medical Center
      2014   -   NCT02125851   United States
Zofran - NO intubation
   Children's Hospital Medical Center, Cincinnati
      2009   -   NCT02038894   United States